Shares of biotech giant Amgen, Inc. (NASDAQ:AMGN), while higher by roughly 19% for the year, also remains a pain trade for momentum-chasing traders as well as longer-term investors. Yet, if one looks at the broader large-cap biotech …
AMGN Stock: The Completed Technical Price Pattern Points Towards Higher Stock Prices This time last year, the biotechnology stocks were out of favor and lagging behind the market indices. A lot has changed since then because …
AMGN has reported positive but preannounced Repatha data, which disappointed investors. With the stock off to $168-169, I analyze it as not yet a good source of alpha. That's due to my review of the FOURIER outcomes study as good but …
While the S&P 500 continues to rally to new highs for the year, biotech stocks continue to languish. One of the biggest names in biotech, Amgen, Inc. ( AMGN) continues to trade sideways in an ever narrowing range. I look for this period of …
Biotech major Amgen Inc. AMGN will report third-quarter 2017 results on Oct 25 ... show that Amgen is likely to beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESPand a Zacks Rank #1 …
Large-capitalization biotechnology stocks as represented by the iShares Nasdaq Biotechnology Index (ETF) (NASDAQ:IBB) lifted on Thursday on the back of comments from the Independent Payment Advisory Board said that …